Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2015, Vol. 6 Issue (4) : 236-244     DOI: 10.14336/AD.2014.1004
Original Article |
Clinical Characteristics for the Relationship between Type-2 Diabetes Mellitus and Cognitive Impairment: A Cross-Sectional Study
Zhou Yi1, Fang Rong1, Liu Li-Hua2, Chen Sheng-Di1,*, Tang Hui-Dong1,*
1Department of Neurology, Rui Jin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China
2Department of Neurology, the People's Hospital of Jurong City, Zhenjiang, 212400, China
Download: PDF(950 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

We explored the potential differences in cognitive status, lipid and glucose metabolism, ApoEε4 alleles and imaging between diabetic and non-diabetic subjects. 83 subjects with normal cognitive function and 114 mild cognitive impaired patients were divided into four groups by history of diabetes. General demographics was collected from all participants followed by MRI scan, biochemical examinations and a series of neuropsychological tests. Student’s t test, multiple regressions and one-way ANOVA were applied to investigate the differences between groups. Comparing diabetic patients with non-diabetic subjects in the mild cognitive impaired group, we found several decreased items in recall of three words in MMSE (p=0.020), AVLT and SCWT (p<0.050). The multiple linear regression revealed that two-hour glucose level (B= -0.255,p<0.001) and fasting C-peptide (B= -0.466,p=0.001) had negative effects on the score of MMSE. In addition, diabetic patients treated with insulin and other diabetes medication performed better in part of the AVLT (p<0.050) compared to patients with insulin treatment or oral antidiabetic medication only. Patients with metformin medication had a better memory outcome compared to patients with sulphonylurea medication in the AVLT long delay free recall (p =0.010). These findings show that patients of mild cognitive impairment with diabetes mellitus have a worse outcome in attention, information processing speed and memory compared to non-diabetic patients. Higher two-hour glucose level and C-peptide level may be risk factors for severe cognitive impairment in type-2 diabetes mellitus patients. The results of this study also suggest that medication may have effects on cognitive function.

Keywords Type-2 diabetes mellitus      mild cognitive impairment      C-peptide      blood glucose     
Corresponding Authors: Chen Sheng-Di,Tang Hui-Dong   
About author:

present address: Kunming Biomed International, Kunming, Yunnan, 650500, China

Issue Date: 01 August 2015
E-mail this article
E-mail Alert
Articles by authors
Zhou Yi
Fang Rong
Liu Li-Hua
Chen Sheng-Di
Tang Hui-Dong
Cite this article:   
Zhou Yi,Fang Rong,Liu Li-Hua, et al. Clinical Characteristics for the Relationship between Type-2 Diabetes Mellitus and Cognitive Impairment: A Cross-Sectional Study[J]. Aging and disease, 2015, 6(4): 236-244.
URL:     OR
Figure 1.  Brain MRI: measurement of the interuncal distance (IUD) and the intracranial width (ICW). IUD and ICW were acquired at the suprasellar stern level from the axial T1 images. The measurement of IUD is indicated by the black arrows and the ICW by the white arrows.
Total numberMale(female)Age (yrs)Education
APOE ε4 (+) carriers (%)
Table 1A  Comparison of demographic information between control and mild cognitive impairment groups
mmol/Lmmol/Lμl U/mlμl U/ml%ng/ml
Table 1B  Comparison of glucose metabolism between control and mild cognitive impairment groups
Table 1C  Comparison of lipid metabolism between control and mild cognitive impairment groups
Table 1D  Comparison of lipid metabolism between control and mild cognitive impairment groups
Recall in MMSE (3 words)2.04 ± 0.841.57 ± 1.080.020*
MMSE total score27.12 ± 2.3525.84 ± 3.580.099
AVLT immediate recall
(36 words)
13.05 ± 5.0810.89 ± 3.870.066
AVLT 5-minute recall
(5 min/12 words)
3.55 ± 2.832.41 ± 2.010.031*
AVLT long delay free recall
(20 min/12 words)
3.03 ± 2.791.93 ± 1.890.049*
AVLT long delay cued recall0.55 ± 1.310.74 ± 1.220.379
SCWT-A performance time (s)30.86 ± 10.7736.26 ± 13.860.035*
SCWT-A correct number (50)49.13 ± 3.0748.17 ± 7.770.750
SCWT-B performance time (s)45.56 ± 13.3851.50 ±21.160.253
SCWT-B correct number (50)48.54 ± 2.9344.73 ± 10.980.046*
SCWT-C performance time (s)91.47 ± 36.3100.88 ±58.820.688
SCWT-C correct number (50)44.72 ± 8.0243.18 ± 9.560.457
Table 2  Comparison of cognitive function between MCI patients without diabetes and MCI patients with diabetes
Table 3  Correlation between MMSE scores and clinical characteristics
Insulin treatment onlyOral antidiabetic medication onlyCombined treatmentANOVA
AVLT immediate recall (36 words)14.70 ± 5.1712.83 ± 5.0316.75 ± 5.63F = 2.406
p = 0.097
AVLT 5-minute recall
(5 min/12 words)
3.90 ± 3.283.78 ± 2.655.25 ± 2.86F = 1.000
p = 0.373
AVLT long delay free recall (20 min/12 words)3.50 ± 3.033.33 ± 2.704.75 ± 3.28F = 0.905
p = 0.409
AVLT long delay cued recall0.40 ± 0.701.17 ± 1.813.38 ± 2.26F = 6.971
*p = 0.002
performance time (s)
31.80 ± 12.5632.20 ± 12.1126.75 ± 7.07F = 0.729
p = 0.486
correct number (50)
50.00 ± 0.0048.72 ± 6.8049.75 ± 0.71F = 0.260
p = 0.772
performance time (s)
41.90 ± 11.1347.96 ± 18.9534.86 ± 6.75F = 2.286
p =0.110
correct number (50)
49.70 ± 0.9546.52 ± 7.7349.88 ± 0.35F = 1.556
p = 0.219
performance time (s)
73.20 ± 20.3692.83 ± 50.3568.88 ± 21.50F = 1.547
p = 0.220
correct number (50)
46.10 ± 6.5744.10 ± 8.9547.00 ± 2.51F = 0.595
p = 0.555
Table 4  Comparison of cognitive functions between insulin, oral anti-diabetic therapy and combined therapy groups
[1] Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler MM (1999). Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology, 53: 1937-1942
[2] Velayudhan L, Poppe M, Archer N, Proitsi P, Brown RG, Lovestone S (2010). Risk of developing dementia in people with diabetes and mild cognitive impairment. The British journal of psychiatry : the journal of mental science, 196: 36-40
[3] Luchsinger JA, Reitz C, Patel B, Tang MX, Manly JJ, Mayeux R (2007). Relation of diabetes to mild cognitive impairment. Archives of neurology, 64: 570-575
[4] Cheng G, Huang C, Deng H, Wang H (2012). Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Internal medicine journal, 42: 484-491
[5] Kidd PM (2008). Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Alternative medicine review : a journal of clinical therapeutic, 13: 85-115
[6] Samaras K, Sachdev PS (2012). Diabetes and the elderly brain: sweet memories? Therapeutic advances in endocrinology and metabolism, 3: 189-196
[7] Sima AA, Kamiya H, Li ZG (2004). Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes. European journal of pharmacology, 490: 187-197
[8] Martins IJ, Hone E, Foster JK, Sunram-Lea SI, Gnjec A, Fuller SJ,et al. (2006). Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Molecular psychiatry, 11: 721-736
[9] Bornstein NM, Brainin M, Guekht A, Skoog I, Korczyn AD (2014). Diabetes and the brain: issues and unmet needs. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 35: 995-1001
[10] Umegaki H (2014). Type 2 diabetes as a risk factor for cognitive impairment: current insights. Clinical interventions in aging, 9: 1011-1019
[11] Alberti KG, Zimmet PZ (1998). Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic medicine : a journal of the British Diabetic Association, 15: 539-553
[12] Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999). Mild cognitive impairment: clinical characterization and outcome. Archives of neurology, 56: 303-308
[13] Ma J, Zhou Y, Xu J, Liu X, Wang Y, Deng Y,et al. (2014). Association study of TREM2 polymorphism rs75932628 with late-onset Alzheimer's disease in Chinese Han population. Neurological research: 1743132814Y0000000376
[14] Dahlbeck JW, McCluney KW, Yeakley JW, Fenstermacher MJ, Bonmati C, Van Horn G, 3rd, et al. (1991). The interuncal distance: a new MR measurement for the hippocampal atrophy of Alzheimer disease. AJNR. American journal of neuroradiology, 12: 931-932
[15] Mu Q, Xie J, Wen Z, Weng Y, Shuyun Z (1999). A quantitative MR study of the hippocampal formation, the amygdala, and the temporal horn of the lateral ventricle in healthy subjects 40 to 90 years of age. AJNR. American journal of neuroradiology, 20: 207-211
[16] Cui GH, Yao YH, Xu RF, Tang HD, Jiang GX, Wang Y,et al. (2011). Cognitive impairment using education-based cutoff points for CMMSE scores in elderly Chinese people of agricultural and rural Shanghai China. Acta neurologica Scandinavica, 124: 361-367
[17] Guo Q, Zhao Q, Chen M, Ding D, Hong Z (2009). A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer disease and associated disorders, 23: 253-259
[18] Morris JC (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43: 2412-2414
[19] Guo Q HZ, Lv C,et al. (2005). Application of Stroop color-word test on Chinese elderly patients with mild cognitive impairment and mild Alzheimer's dementia. Chin J Neuromed, 4: 701-704
[20] Zhao WQ, Alkon DL (2001). Role of insulin and insulin receptor in learning and memory. Molecular and cellular endocrinology, 177: 125-134
[21] Derakhshan F, Toth C (2013). Insulin and the brain. Current diabetes reviews, 9: 102-116
[22] Muller AP, Gnoatto J, Moreira JD, Zimmer ER, Haas CB, Lulhier F,et al. (2011). Exercise increases insulin signaling in the hippocampus: physiological effects and pharmacological impact of intracerebroventricular insulin administration in mice. Hippocampus, 21: 1082-1092
[23] Niwa H, Koumoto C, Shiga T, Takeuchi J, Mishima S, Segawa T,et al. (2006). Clinical analysis of cognitive function in diabetic patients by MMSE and SPECT. Diabetes research and clinical practice, 72: 142-147
[24] Xia W, Wang S, Sun Z, Bai F, Zhou Y, Yang Y,et al. (2013). Altered baseline brain activity in type 2 diabetes: a resting-state fMRI study. Psychoneuroendocrinology, 38: 2493-2501
[25] Hills CE, Brunskill NJ (2009). Cellular and physiological effects of C-peptide. Clinical science, 116: 565-574
[26] Sima AA (2003). C-peptide and diabetic neuropathy. Expert opinion on investigational drugs, 12: 1471-1488
[27] Shpakov AO, Granstrem OK (2013). [C-peptide physiological effects]. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova / Rossiiskaia akademiia nauk, 99: 196-211
[28] Shpakov AO, Granstrem AO (2013). [C-peptide structure, functions and molecular mechanisms of action]. Tsitologiia, 55: 16-27
[29] Crane PK, Walker R, Larson EB (2013). Glucose levels and risk of dementia. The New England journal of medicine, 369: 1863-1864
[30] Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Floel A (2013). Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology, 81: 1746-1752
[31] Mortby ME, Janke AL, Anstey KJ, Sachdev PS, Cherbuin N (2013). High "normal" blood glucose is associated with decreased brain volume and cognitive performance in the 60s: the PATH through life study. PloS one, 8: e73697
[32] Roberts RO, Geda YE, Knopman DS, Christianson TJ, Pankratz VS, Boeve BF,et al. (2008). Association of duration and severity of diabetes mellitus with mild cognitive impairment. Archives of neurology, 65: 1066-1073
[33] Plastino M, Fava A, Pirritano D, Cotronei P, Sacco N, Sperli T,et al. (2010). Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. Journal of the neurological sciences, 288: 112-116
[34] Beeri MS, Schmeidler J, Silverman JM, Gandy S, Wysocki M, Hannigan CM,et al. (2008). Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology, 71: 750-757
[35] He L, Sabet A, Djedjos S, Miller R, Sun X, Hussain MA,et al. (2009). Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell, 137: 635-646
[36] Labuzek K, Suchy D, Gabryel B, Bielecka A, Liber S, Okopien B (2010). Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacological reports : PR, 62: 956-965
[37] Pintana H, Apaijai N, Pratchayasakul W, Chattipakorn N, Chattipakorn SC (2012). Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life sciences, 91: 409-414
[1] Calvin Pak-Wing Cheng, Sheung-Tak Cheng, Cindy Woon-Chi Tam, Wai-Chi Chan, Winnie Chiu-Wing Chu, Linda Chiu-Wa Lam. Relationship between Cortical Thickness and Neuropsychological Performance in Normal Older Adults and Those with Mild Cognitive Impairment[J]. Aging and disease, 2018, 9(6): 1020-1030.
[2] Xue Jiang, Li Jiarui, Liang Jiaming, Chen Shulin. The Prevalence of Mild Cognitive Impairment in China: A Systematic Review[J]. Aging and disease, 2018, 9(4): 706-715.
[3] Sternberg Zohara, Hu Zihua, Sternberg Daniel, Waseh Shayan, Quinn Joseph F., Wild Katharine, Jeffrey Kaye, Zhao Lin, Garrick Michael. Serum Hepcidin Levels, Iron Dyshomeostasis and Cognitive Loss in Alzheimer’s Disease[J]. Aging and disease, 2017, 8(2): 215-227.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd